Stockscreener 앱 받기
8.27
2.59%
-0.22
시간 외 거래:
8.31
0.04
+0.48%
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Cantor Fitzgerald L. P. Buys Shares of 201,865 Ocular Therapeutix, Inc. $OCUL - MarketBeat
VR Adviser Reduces Ocular Therapeutix Stake in Q4 2025 | Portfolio ImpactNews and Statistics - IndexBox
Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down - Yahoo Finance
Is It Time To Reassess Ocular Therapeutix (OCUL) After Its Recent Share Price Slide - Yahoo Finance
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 20.0% in February - MarketBeat
Ocular Therapeutix Stock & Financial Performance Review 2026News and Statistics - IndexBox
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead - Yahoo Finance
A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness - simplywall.st
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
201,865 Shares in Ocular Therapeutix, Inc. $OCUL Bought by Cantor Fitzgerald L. P. - MarketBeat
Is Ocular Therapeutix (OCUL) Pricing Reflect Its Volatile Returns And Rich Sales Multiple? - simplywall.st
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Purchased by Avoro Capital Advisors LLC - MarketBeat
Ocular Therapeutix Opens with 8.61% Gain Amid Ongoing Financial Challenges - Markets Mojo
Ocular Therapeutix Gets Black Eye, But I See Stock Rising on New Drug - TheStreet Pro
Rosalind Advisors Inc. Decreases Stock Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular Therapeutix at The Citizens Life Sciences Conference: AXPAXLI’s Promising Results - Investing.com Canada
OCUL: AXPAXLI's phase III success sets a new standard in wet AMD, with regulatory approval in progress - TradingView
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rhenman & Partners Asset Management AB Buys Shares of 202,000 Ocular Therapeutix, Inc. $OCUL - MarketBeat
Can Ocular Therapeutix Inc. stock surprise with earnings upsideJuly 2025 Intraday Action & Technical Buy Zone Confirmation - Naître et grandir
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why Ocular Therapeutix (OCUL) Is Up 16.2% After Detailing Retinal Pipeline Progress And Upcoming Milestones - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Bought by Vanguard Group Inc. - MarketBeat
New Ocular Therapeutix Price Target as Stock Prepares to Blow Through the Old One - TheStreet Pro
Ocular Therapeutix, Inc. (OCUL) Competitors - Meyka
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula SocietySlideshow - Seeking Alpha
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest - DirectorsTalk Interviews
Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings - TIKR.com
Ocular Therapeutix (OCUL): Analyst Raises Price Target Amid Stea - GuruFocus
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Grows By 27.8% - MarketBeat
William Blair Maintains Outperform on Ocular Therapeutix, Inc. (OCUL) March 2026 - Meyka
Ocular Therapeutix Breaks Above 200-Day Moving AverageBullish for OCUL - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 17.4%Should You Buy? - MarketBeat
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix at TD Cowen Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Canada
OCUL: Superiority achieved in retina study, paving way for broad label and premium market position - TradingView
Citigroup Inc. Buys 573,504 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix Director Pravin Dugel Sells Shares - TradingView
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Swings And AXPAXLI Expectations - Yahoo Finance
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory - Yahoo Finance
Ocular Therapeutix Shares Fall After Inflation Report | 2026 Market UpdateNews and Statistics - IndexBox
Ocular Therapeutix (NASDAQ:OCUL) Cut to Sell at Wall Street Zen - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Ocular Therapeutix (OCUL) Pricing Reflecting Its Recent Volatility And DCF Implied Upside - simplywall.st
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why - Yahoo Finance
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress - TipRanks
Ocular Therapeutix to Release SOL-1 Phase 3 AXPAXLI Trial Slides at Macula Society Meeting - TradingView
Ocular Therapeutix chief development officer Kaiser sells $23k in stock - Investing.com India
Sanjay Nayak Sells 1,759 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Peter Kaiser Sells 2,810 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Jeffrey Heier Sells 3,057 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):